
UNH
- Market cap
- $472B
- Sector
- Health care

Based on 34 analysts for FY2026
Dollars per share. The record, then the analysts' mean; the dashed lines are their lowest and highest estimate; Oryn's base case is the accent line.
Illustrative estimates; Oryn's line is the base case its DCF run of 8 Sep 2026 stored
Solid, filled: reported, then the consensus meanDashed: the lowest and highest estimateAccent: Oryn's base case, as its DCF run stored it
Oryn's base case against the consensus mean, earnings per share
Each year on one scale, as a difference from that year's consensus mean (the ink line, 0%). The accent mark is Oryn's base case; the grey band is its bear-to-bull range.
Illustrative estimates and paths
Oryn's bear, base and bull are the cases its DCF run of 8 Sep 2026 stored (run run-unh-), year by year. A "Consensus" year is one the run took from the analysts' panel; a "Fade" year is the run's own past it.
Oryn's EPS is each case's net income over the run's 0.92B shares outstanding, counted on 8 Sep 2026; the analysts' EPS is diluted, so at equal earnings Oryn's reads a little higher.
Where this page's consensus covers the year, Oryn's base case is up to +5.3% from its mean: the run read the consensus as of its own date and divides by its own share count.
FY2029–FY2030: the run's fade past the analysts' panel, growth narrowing toward its terminal rate with the margin held.
| Fiscal year | Reported | Consensus low | Consensus mean | Consensus high | Analysts | Oryn bear | Oryn base | Oryn bull | Base vs consensus | Oryn year from |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2021 | $16.97 | — | — | — | — | — | — | — | — | — |
| FY2022 | $17.49 | — | — | — | — | — | — | — | — | — |
| FY2023 | $18.67 | — | — | — | — | — | — | — | — | — |
| FY2024 | $19.36 | — | — | — | — | — | — | — | — | — |
| FY2025 | $20.57 | — | — | — | — | — | — | — | — | — |
| FY2026 | — | $21.03 | $22.59 | $24.19 | 34 | $21.24 | $22.82 | $24.43 | +1.0% | Consensus |
| FY2027 | — | $21.98 | $24.78 | $27.80 | 28 | $22.20 | $25.79 | $28.08 | +4.1% | Consensus |
| FY2028 | — | $23.02 | $27.06 | $31.70 | 22 | $23.25 | $28.50 | $32.02 | +5.3% | Consensus |
| FY2029 | — | — | — | — | — | $23.66 | $29.60 | $33.55 | — | Fade |
| FY2030 | — | — | — | — | — | $24.19 | $30.27 | $34.30 | — | Fade |
Q3 FY2026, from 36 analysts
Moved in ninety days
4 quarters and 3 fiscal years
| Period | Revenue | Earnings per share | Analysts | Revision, 90 days |
|---|---|---|---|---|
| Quarters | ||||
| Q3 FY2026 | $116.29B | $5.90 | 36 | +2.0% |
| Q4 FY2026 | $123.26B | $6.26 | 34 | +2.3% |
| Q1 FY2027 | $113.89B | $5.92 | 32 | −0.9% |
| Q2 FY2027 | $117.47B | $6.10 | 30 | +2.3% |
| Fiscal years | ||||
| FY2026 | $454.31B | $22.59 | 34 | +1.5% |
| FY2027 | $477.03B | $24.78 | 28 | −0.8% |
| FY2028 | $499.93B | $27.06 | 22 | +2.2% |
| Period | Revenue | Estimate | Surprise | Earnings per share | Estimate | Surprise | Analysts |
|---|---|---|---|---|---|---|---|
| Quarters | |||||||
| Q2 FY2026 | $109.04B | $108.07B | +0.9% | $5.30 | $5.12 | +3.5% | 33 |
| Q1 FY2026 | $105.72B | $105.59B | +0.1% | $5.13 | $5.29 | −3.0% | 30 |
| Q4 FY2025 | $117.34B | $118.51B | −1.0% | $5.69 | $5.49 | +3.6% | 35 |
| Q3 FY2025 | $110.70B | $108.74B | +1.8% | $5.37 | $5.37 | +0.0% | 30 |
| Fiscal years | |||||||
| FY2025 | $428.50B | $433.25B | −1.1% | $20.57 | $20.48 | +0.4% | 36 |
| FY2024 | $400.30B | $399.29B | +0.3% | $19.36 | $18.52 | +4.5% | 40 |
Target range vs price
The grey band spans the lowest and highest published target; the marked figure is the mean of 26 targets and the vertical line is today’s price.
Published targets collected to 9 Sep 2026 · third-party; not an Oryn output